RTC
REGN icon

Riverview Trust Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Riverview Trust Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74K Hold
6
– – ﹤0.01% 162
2026
Q1 		$4.64K Hold
6
– – 0.01% 185
2025
Q4 		$4.63K Hold
6
– – 0.01% 200
2025
Q3 		$3.37K Hold
6
– – ﹤0.01% 193
2025
Q2 		$3.15K Sell
6
-80
-93% -$44.7K ﹤0.01% 212
2025
Q1 		$54.5K Hold
86
– – 0.05% 212
2024
Q4 		$61.3K Sell
86
-24
-22% -$20.1K 0.06% 203
2024
Q3 		$116K Buy
110
+2
+2% +$2.23K 0.1% 152
2024
Q2 		$114K Buy
108
+34
+46% +$33K 0.11% 145
2024
Q1 		$71.2K Buy
+74
New +$70.4K 0.05% 200
2023
Q4 		– Sell
-74
Closed -$60.9K – 515
2023
Q3 		$60.9K Hold
74
– – 0.05% 211
2023
Q2 		$53.2K Hold
74
– – 0.05% 200
2023
Q1 		$60.8K Hold
74
– – 0.06% 185
2022
Q4 		$53K Hold
74
– – 0.05% 209
2022
Q3 		$51K Hold
74
– – 0.05% 203
2022
Q2 		$44K Hold
74
– – 0.04% 231
2022
Q1 		$52K Buy
+74
New +$46.8K 0.04% 217

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Riverview Trust Company's REGN Position: Q2 2026 in Review

Riverview Trust Company held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 6 shares worth $3.74K. The position accounts for ﹤0.01% of the portfolio, ranked #162.

Riverview Trust Company first reported a position in REGN in Q1 2022 and has held it in 17 quarters since. The position peaked at $116K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Riverview Trust Company held 6 shares of Regeneron Pharmaceuticals worth $3.74K as of Q2 2026.
  • Riverview Trust Company left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Riverview Trust Company's portfolio in Q2 2026, its #162 holding.
  • Riverview Trust Company first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Riverview Trust Company's Regeneron Pharmaceuticals position peaked at $116K in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Riverview Trust Company's 13F filing for Q2 2026, filed 3 Aug 2026.